Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Head & Neck 1

Conditions

Salivary Gland Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 28Nivolumab 13Carboplatin 9fludarabine 7Paclitaxel 7Gemcitabine 7Docetaxel 7Cyclophosphamide 7Cisplatin 7Trastuzumab 5palbociclib 4cemiplimab 4avelumab 4atezolizumab 4Ipilimumab 4Fluorouracil 4Filgrastim 4Drug Therapy 4Cetuximab 4fludarabine phosphate 3epacadostat 3durvalumab 3Taxes 3Oxaliplatin 3Fulvestrant 3zimberelimab 2ulixertinib 2trametinib 2tisotumab vedotin 2spartalizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × RC48 antibody × Head & Neck × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡